Summit Trail Advisors LLC Purchases 294 Shares of DaVita Inc. (NYSE:DVA)

Summit Trail Advisors LLC increased its stake in DaVita Inc. (NYSE:DVA) by 1.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 23,309 shares of the company’s stock after purchasing an additional 294 shares during the quarter. Summit Trail Advisors LLC’s holdings in DaVita were worth $3,821,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. BOKF NA grew its position in shares of DaVita by 286,550.0% in the first quarter. BOKF NA now owns 5,733 shares of the company’s stock valued at $790,000 after purchasing an additional 5,731 shares in the last quarter. Assenagon Asset Management S.A. grew its position in DaVita by 29.6% during the second quarter. Assenagon Asset Management S.A. now owns 50,096 shares of the company’s stock worth $6,942,000 after buying an additional 11,454 shares in the last quarter. Comerica Bank grew its position in DaVita by 41.4% during the first quarter. Comerica Bank now owns 34,431 shares of the company’s stock worth $4,753,000 after buying an additional 10,074 shares in the last quarter. MBB Public Markets I LLC purchased a new position in DaVita during the second quarter worth about $582,000. Finally, Chase Investment Counsel Corp grew its position in DaVita by 56.3% during the third quarter. Chase Investment Counsel Corp now owns 33,084 shares of the company’s stock worth $5,423,000 after buying an additional 11,912 shares in the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Trading Up 0.8 %

Shares of DVA stock opened at $165.51 on Friday. The business has a 50-day moving average of $158.31 and a 200 day moving average of $148.36. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. DaVita Inc. has a 1-year low of $98.26 and a 1-year high of $168.50. The stock has a market capitalization of $13.57 billion, a PE ratio of 17.85, a P/E/G ratio of 0.93 and a beta of 0.89.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The company had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. During the same period last year, the company posted $2.85 EPS. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that DaVita Inc. will post 9.71 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. UBS Group boosted their target price on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Barclays upped their price objective on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Bank of America upped their price objective on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. Finally, Truist Financial upped their price objective on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $161.80.

Insiders Place Their Bets

In other news, CEO Javier Rodriguez sold 32,176 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the completion of the sale, the chief executive officer now directly owns 905,659 shares in the company, valued at approximately $141,219,407.87. This represents a 3.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Joel Ackerman sold 64,029 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total value of $9,928,336.74. Following the transaction, the chief financial officer now owns 111,481 shares in the company, valued at approximately $17,286,243.86. This represents a 36.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 156,086 shares of company stock valued at $24,807,161 in the last quarter. Insiders own 2.00% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.